Causal Roles of CLEC5A and ISG20 in Atherosclerosis: Evidence from Mendelian Randomization and eQTL Integration

Study Background and Research Question

Atherosclerosis (AS) remains a leading cause of cardiovascular mortality, characterized by lipid build-up and chronic inflammation in the arterial wall. Despite advances in genomics and immunology, the interplay between genetic risk factors and immune regulation in AS pathogenesis is still incompletely understood. The reference study by Zhang et al. (2025) addresses this gap by systematically identifying genes that both associate with and causally influence AS, focusing on immune- and inflammation-related candidates.

Key Innovation from the Reference Study

The study's principal innovation lies in its integrative approach, combining gene expression data, expression quantitative trait locus (eQTL) mapping, and Mendelian randomization (MR) to establish not just correlation but causality between gene expression and AS risk. This rigorous framework allowed the authors to pinpoint two genes—CLEC5A and ISG20—as causal drivers of atherosclerosis progression, with ISG20 highlighted for its mechanistic role in macrophage-mediated lipid accumulation and inflammatory signaling. Such multidimensional evidence elevates these genes from statistical associations to functionally validated targets for further investigation and therapeutic exploration.

Methods and Experimental Design Insights

The study began by mining the Gene Expression Omnibus (GEO) for datasets profiling gene expression in atherosclerotic tissues. Differentially expressed genes were identified and cross-referenced with eQTL data to link expression patterns to specific genetic variants. Mendelian randomization, a statistical method leveraging natural genetic variation as an instrumental variable, was then utilized to infer causal relationships between gene expression and AS risk.

Significant candidates were subjected to functional enrichment analyses, revealing overrepresentation in immune response, inflammatory pathways, and lipid metabolism. For biological validation, the authors employed both in vitro and in vivo models: oxidized low-density lipoprotein (ox-LDL)-stimulated macrophages and apolipoprotein E-deficient (ApoE–/–) mice, a standard model for atherosclerosis. Expression levels of CLEC5A and ISG20 were assessed using Western blotting and RT-qPCR, while spatial localization in atherosclerotic plaques was visualized via immunofluorescence and immunohistochemistry. These steps ensured both quantitative and spatial resolution of gene expression relevant to disease pathology.

Core Findings and Why They Matter

The integrated analysis identified significant upregulation of CLEC5A and ISG20 in AS patients. MR analysis provided statistical evidence for a positive causal relationship between increased expression of both genes and heightened AS risk (CLEC5A: OR = 1.001, P = 0.047; ISG20: OR = 1.001, P = 0.030). Conversely, HOXA2 was negatively associated with disease risk. Functional assays confirmed notably elevated ISG20 expression in both ox-LDL-treated macrophages and atherosclerotic mouse lesions, particularly in cell-rich regions marked by endothelial and macrophage markers.

Importantly, the study is the first to directly implicate ISG20 in promoting atherosclerosis through enhancement of macrophage lipid uptake and amplification of inflammatory pathways. These mechanistic insights position ISG20 as a potential target for therapeutic intervention, underscoring the value of integrating genomic, transcriptomic, and functional validation pipelines in cardiovascular research (Zhang et al., 2025).

Comparison with Existing Internal Articles

This study complements and extends observations previously discussed in internal summaries, which outlined the causal roles of CLEC5A and ISG20 in atherogenesis. In contrast to earlier literature that primarily described statistical associations, Zhang et al. provide robust causal inference and experimental confirmation, bridging the gap between genetic predisposition and pathological mechanism. Additionally, the detailed immunodetection approaches adopted align with technical recommendations in "HyperFluor™ 594 Goat Anti-Rabbit IgG: Precision in ICC & IHC", which emphasizes the necessity of high-specificity detection systems—such as goat anti-rabbit IgG secondary antibodies—in dissecting disease pathways at the cellular level.

Furthermore, the study's use of immunofluorescence to localize ISG20 within atherosclerotic plaques echoes the methodological frameworks highlighted in "Advancing Biomimetic PDT: Precision Detection with HyperFluor™ 594", reinforcing the growing importance of multiplexed, fluorescence-based detection in cardiovascular and translational research.

Limitations and Transferability

While the integration of MR, eQTL, and experimental validation is a methodological strength, some limitations must be acknowledged. First, the MR approach relies on the validity of the instrumental variables and the absence of pleiotropy; undetected confounders may bias causal inference. The experimental validations, though robust, are restricted to specific macrophage models and ApoE–/– mice, which, while widely used, may not fully recapitulate human disease complexity. The transferability of findings to diverse patient populations or to other immune-mediated vascular diseases remains to be established. Moreover, although ISG20 emerges as a promising target, its broader biological roles—especially in antiviral defense—necessitate careful evaluation to avoid unintended systemic effects.

Protocol Parameters

• Gene expression analysis: Use curated atherosclerotic tissue datasets from GEO; ensure differential expression is validated by qPCR or RNA-seq in independent cohorts.
• Mendelian randomization: Employ genome-wide significant SNPs as instruments; apply sensitivity analyses to assess pleiotropy.
• In vitro macrophage stimulation: Treat primary or immortalized macrophages with 50–100 µg/mL ox-LDL for 24–48 hours prior to RNA/protein extraction.
• Animal models: Utilize ApoE–/– mice on a high-fat diet for at least 8–12 weeks to induce reproducible atherosclerotic plaques before intervention or tissue harvest.
• Immunofluorescence and IHC detection: Employ validated secondary antibodies—such as goat anti-rabbit IgG conjugates—for multiplexed labeling of macrophage and endothelial markers.
• Statistical analysis: Adjust for multiple comparisons and batch effects; validate findings in at least one independent cohort or model system.

Research Support Resources

For researchers aiming to replicate or extend these findings, reliable immunodetection is critical. The HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody (SKU K3305) from APExBIO offers robust fluorescence performance (excitation 590 nm, emission 617 nm) and high specificity, facilitating sensitive detection in immunocytochemistry, immunohistochemistry, flow cytometry, and ELISA applications. Its validated protocol compatibility supports workflows similar to those described by Zhang et al., providing clarity and reproducibility in cellular localization studies of disease-associated proteins.